Targets › CD137
4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Apr 2027.
Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable). (UniProt, Q07011)
Open in Phaseline: the race on CD137, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hadassah Medical Organization | A2/4-1BBL melanoma vaccine 4-1BBL expressing melanoma cell vaccine | CD137 | Phase 1 | Malignant Melanoma | Apr 2027 |
| Zhou Chengzhi | Karelizumab CD137 (4-1BB) agonist antibody | CD137 | Phase 1 | Lung Cancer | Aug 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | AGEN2373 CD137 (4-1BB) agonist antibody | CD137 | Phase 1 | Pancreatic Cancer | Dec 2028 |
| Adagene | ADG206 activatable anti-CD137 monoclonal antibody (IgG1 co-stimulatory agonist) | CD137 | Phase 1 | Advanced/Metastatic Solid Tumors | – |
Lung Cancer (1) Pancreatic Cancer (1) Advanced/Metastatic Solid Tumors (1) Malignant Melanoma (1)
mixed (2), antibody (1), small molecule (1)
Zhou Chengzhi (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) Adagene (1) Hadassah Medical Organization (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.